Please login to the form below

Not currently logged in
Email:
Password:

Aelix Therapeutics appoints Dr Thomas Hecht

He joins the Spanish biotech as chairman of the board of directors

Thomas MechtSpanish biotech Aexlis Therapeutics has appointed Dr Thomas Hecht as chairman of its board of directors, a role that will see him support the company in establishing proof-of-concept for its HIV vaccine.

Dr Hecht expertise includes leading value creation processes for stakeholders and deal making with pharmaceutical and biotech companies.

He said: “Aelix Therapeutics has reached a crucial milestone by enrolling the first patient in the phase I clinical trial and I’m thrilled to be joining the company at this exciting time.

“After decades of work to develop a HIV vaccine, I hope to contribute with my experience in building a strong player that I believe has good chances to be amongst the very few which could eventually succeed.”

Dr Hecht has previously served Amgen in various capacities between 1989 and 2002, including head of medical affairs and vice president of marketing at Amgen Europe.

Dr Karen Wagner, member of the board and outgoing chair, said: “I am delighted to welcome Dr Hecht, his extensive experience in managing biotech companies and his broad network of contacts in the pharmaceutical industry will be of great value to the future of Aelix.”

He currently serves as chairman of the supervisory board at Affined, chairman of the board of directors at Cell Medica and Vaximm.

27th October 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...